Scotiabank Lifts Merck (MRK) Target as Execution Continues to Impress

Core Viewpoint - Merck & Co., Inc. (NYSE:MRK) has received a price target increase from Scotiabank, reflecting strong execution despite a cautious outlook for 2026 due to potential revenue pressures from product exclusivity losses [2][3]. Group 1: Financial Performance - Merck reported a strong fourth quarter, exceeding revenue and earnings expectations, primarily driven by demand for its cancer immunotherapy Keytruda [4]. - The company anticipates 2026 revenue to be between $65.5 billion and $67.0 billion, which is below the consensus estimate of $67.6 billion [4]. - Merck expects approximately $2.5 billion in revenue pressure this year due to factors such as increased generic competition, Medicare price negotiations, and declining sales of its COVID-19 treatment, Lagevrio [4]. Group 2: Product Outlook - Management indicated that several drugs, including Januvia and related therapies, may underperform expectations, impacting near-term results [5]. - The company is focusing on longer-term growth drivers across its broader portfolio, despite short-term challenges [5]. Group 3: Company Overview - Merck & Co., Inc. is a global healthcare company that specializes in prescription medicines, including biologic therapies, vaccines, and animal health products, with a strong emphasis on human health drugs and vaccines [6].